Pneumonia prevention interventions such as proper oral care, head-of-bed elevation, and incentive spirometry, are not being provided to most patients outside the ICU, leading to greater than two-thirds of hospital-acquired pneumonia.
An increasing body of subsequent research has challenged the usefulness of the healthcare-associated pneumonia label, including studies that have cast doubt on links between multidrug-resistant pathogens and increased mortality.
A multidisciplinary panel of experts put together by the American Thoracic Society and Infectious Diseases Society of America released updated recommendations for the management of adults with community-acquired pneumonia.
A clinical trial conducted in 5 countries assessed the benefit of combining interferon β-1a with remdesivir to treat inpatients with COVID-19 pneumonia.
